| Literature DB >> 26974321 |
Xiong Li1, Jin Zhao2, Jianxing Liu3, Geng Li3, Ya Zhao1,4, Xing Zeng1.
Abstract
Ultra-high-pressure liquid chromatography (UHPLC) was coupled with linear ion trap quadrupole Orbitrap mass spectrometry (LTQ-Orbitrap) and was used for the first time to systematically analyze the absorbed components and metabolites in rat plasma after oral administration of the water extract of Sarcandra glabra. This extract is a well-known Chinese herbal medicine for the treatment of inflammation and immunity related diseases. The anti-inflammatory activities of the absorbed components were evaluated by measuring nitric oxide (NO) production and proinflammatory genes expression in lipopolysaccharide (LPS)-stimulated murine RAW 264.7 macrophages. As a result, 54 components in Sarcandra glabra were detected in dosed rat plasma, and 36 of them were positively identified. Moreover, 23 metabolites were characterized and their originations were traced. Furthermore, 20 of the 24 studied components showed anti-inflammatory activities. These results provide evidence that this method efficiency detected constituents in plasma based on the anti-inflammatory mechanism of multiple components and would be a useful technique for screening multiple targets for natural medicine research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26974321 PMCID: PMC4790918 DOI: 10.1371/journal.pone.0150063
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The strategy for systematic screening and identification of the absorbed constituents and metabolites in S. glabra by UHPLC–LTQ-Orbitrap
Fig 2UHPLC-DAD chromatograms: (a) blank plasma; (b) drug-containing plasma after oral administration of S. glabra.
Detected metabolites of 18, 21, 45, 54, 56, 57 and 64 in rat plasma after oral administration in single or extract forms.
| t | Parent ion | MS/MS data | Identification | Origination | ||
|---|---|---|---|---|---|---|
| 18.0 | 353.1 | 191.1(100), 178.8(25),173.0(36) | √ | √ | ||
| 21.1 | 179.1 | 135.0 (100) | caffeic acid ( | √ | √ | |
| 17.9 | 355.1 | 311.1 (100), 179.0 (38) | caffeic acid glucuronide 1 ( | √ | √ | |
| 18.9 | 355.1 | 311.2 (100), 179.1 (30), 175.0 (15) | caffeic acid glucuronide 2 ( | √ | √ | |
| 17.3 | 259.1 | 179.1 (100), 128.0 (38) | caffeic acid sulfate 1 ( | √ | √ | |
| 18.2 | 273.1 | 193.1(100), 229.0 (16) | methylated caffeic acid sulfate 1 ( | √ | √ | |
| 18.9 | 273.1 | 193.1(100), 229.0 (17) | methylated caffeic acid sulfate 2 ( | √ | √ | |
| 27.0 | 163.0 | 119.0 (100), | √ | √ | ||
| 27.5 | 165.0 | 147.0 (100), 121.1 (32) | 3-Hydroxyphenylpropionic acid ( | √ | √ | |
| × | √ | |||||
| 28.2 | 221.0 | 206.0 (100) | isofraxidin | √ | √ | |
| 19.1 | 301.0 | 221.1 (100) | isofraxidin-7-O-sulfate ( | √ | √ | |
| 19.5 | 397.1 | 221.1 (100) | isofraxidin -7-O-α-D-glucuronide ( | √ | √ | |
| 28.1 | 221.0 | 206.0 (100) | √ | √ | ||
| 18.7 | 301.0 | 221.1 (100) | isofraxidin-7-O-sulfate ( | √ | √ | |
| 19.1 | 191.1 | 162.9 (100), 135.0 (8) | isofraxidin deoxymethyl conjugation | √ | × | |
| 19.6 | 397.1 | 221.1 (100), 175.0 (10) | isofraxidin -7-O-α-D-glucuronide ( | √ | √ | |
| 34.0 | 359.1 | 161.0 (100), 178.9(32), 197.2(20) | √ | √ | ||
| 28.0 | 535.1 | 359.1 (100) | rosmarinic acid glucuronide 1 ( | √ | × | |
| 31.1 | 535.1 | 359.1 (100) | rosmarinic acid glucuronide | √ | √ | |
| 31.1 | 521.1 | 359.0 (100) | rosmarinic acid-4- | √ | √ | |
| 29.0 | 439.1 | 359.1 (100), 259.2 (80) | rosmarinic acid sulfate ( | √ | × | |
| 32.3 | 549.1 | 373.2 (100), 161.1 (12) | methylated rosmarinic acid glucuronide 1 ( | √ | √ | |
| 36.0 | 549.1 | 373.2 (100), 337.1(60) | methylated rosmarinic acid glucuronide 2 ( | √ | √ | |
| 36.2 | 373.1 | 179.2 (64), 160.9(100), 135.0 (60) | methylated rosmarinic acid ( | √ | × | |
| 18.1 | 259.1 | 179.0 (100), 214.9 (11) | caffeic acid sulfate 2 ( | √ | √ | |
| 12.5 | 261.1 | 181.1(100), 217.1 (86) | dihydrocaffeic acid sulfate ( | √ | √ | |
| 30.2 | 449.1 | 303.2 (100), 285.2(46) | √ | √ | ||
| 15.8 | 625.1 | 479.1 (46), 449.2 (78), 303.1 (100), 285.0 (39) | astilbin glucuronide 1 ( | √ | × | |
| 16.8 | 625.1 | 479.1 (52), 449.2 (49), 303.1 (100), 285.0 (28) | astilbin glucuronide 2 ( | √ | × | |
| 21.7 | 625.1 | 479.1 (34), 449.2 (72), 303.1 (100), 285.0 (28) | astilbin glucuronide 3 ( | √ | × | |
| 23.5 | 625.1 | 479.1 (59), 449.2 (100), 303.1 (60), 285.0 (41) | astilbin glucuronide 4 ( | √ | × | |
| 35.0 | 463.1 | 299.1(100), 317.2 (389) | 3'-O-methylated astilbin ( | √ | × | |
| 19.0 | 639.1 | 493.0 (21), 463.2 (100), 317.2(33),299.2 (12) | methylated astilbin glucuronide 1 ( | √ | × | |
| 20.0 | 639.1 | 493.0 (12), 463.2 (100), 317.2(35),299.2 (11) | methylated astilbin glucuronide 2 ( | √ | × | |
| 24.7 | 639.1 | 493.0 (14), 463.2 (100), 317.2(43),299.0 (11) | methylated astilbin glucuronide 3 ( | √ | × | |
| 26.2 | 639.1 | 493.0 (15), 463.2 (100), 317.2(15),299.1 (10) | methylated astilbin glucuronide 4 ( | √ | × | |
| 31.5 | 521.0 | 359.1 (100) | √ | √ | ||
| 33.7 | 535.1 | 373.1(46), 359.2(100), 341.1(43) | methylated rosmarinic acid-4-O-β-D-glucoside 1 ( | √ | × | |
| 35.1 | 535.1 | 373.1(27), 359.2(100), 341.1(29) | methylated rosmarinic acid-4-O-β-D- glucoside 2 ( | √ | √ | |
| 35.7 | 535.1 | 373.1(100) | methylated rosmarinic acid-4-O-β-D- glucoside 3 ( | √ | √ | |
| 26.8 | 697.1 | 521.0 (100), 359.2 (22) | rosmarinic acid-4-O-β-D-glucoside glucuronide 1 ( | √ | × | |
| 28.6 | 697.1 | 521.0 (100), 359.2 (62) | rosmarinic acid-4-O-β-D-glucoside glucuronide 1 ( | √ | × | |
| 30.6 | 615.1 | 535.2 (35), 453.1 (17), 393.2 (38), 373.2 (27), 273.1 (100) | methylated rosmarinic acid-4-O-β-D-glucoside sulfate ( | √ | √ | |
| 29.3 | 601.1 | 521.1(100), 359.1(53), 259.0 (22) | rosmarinic acid-4-O-β-D-glucoside sulfate ( | √ | × | |
| 31.9 | 477.1 | 301.0 (100) | √ | √ | ||
| 23.2 | 653.2 | 477.1 (100), 301.1 (42) | quercetin-3- | √ | × | |
| 26.3, | 653.2 | 477.2 (100), 301.1 (18) | quercetin-3- | √ | × | |
| 29.4 | 653.2 | 477.2 (100), 301.1 (14) | quercetin-3- | √ | √ | |
| 23.9 | 667.2 | 491.1(100), 315.1(19) | methyl quercetin-3- | √ | × | |
| 26.0 | 667.2 | 491.1 (100), 315.0 (30) | methyl quercetin-3- | √ | × | |
| 31.9 | 667.2 | 491.2 (100) | methyl quercetin-3- | √ | × | |
| 34.6 | 491.1 | 315.1 (100) | methyl quercetin-3- | √ | × | |
| 35.2 | 491.1 | 315.2 (100) | methyl quercetin-3- | √ | × | |
| 36.6 | 491.1 | 315.2 (100) | methyl quercetin-3- | √ | √ | |
| 30.3 | 193.0 | 178.0 (81), 161.0 (100), 148.8 (72),134.0 (52) | isoferulic acid ( | √ | × | |
| 28.6 | 193.0 | 178.1 (58), 161.0 (34), 149.1(100),134.0 (63) | ferulic acid ( | √ | × |
aRefer to the collected plasma after oral administration of the respective standard
bRefer to the collected plasma after oral administration of the extract of S. glabra
cMetabolites were identified by comparing the retention time of reference standards
d Metabolites reported firstly
Fig 3The proposed metabolic pathways of eleutheroside B1 (21), rosmarinic acid-4- O-β-D-glucoside (56) and quercetin-3-O-β-D-glucuronide (57) in rat plasma after oral administration.
Fig 4Effects of 15 metabolites (4, 18, 21, 31, 32, 36+39, 45, 55–57, 64, 82, 88, 89 and 98) on NO production in LPS-stimulated RAW264.7 macrophages.
Cells were treated with LPS (1μg/ml) in the absence or presence of the constituents at different concentrations for 24 h. Amounts of NO were determined using the Griess reagent kits; ++p<0.01,control group vs LPS-stimulated group; +p<0.05,control group vs LPS-stimulated group;**P<0.01, LPS vs LPS plus constituents-treated group. B. Values shown in the graphs are mean ± standard deviation (n = 3).
Fig 5Effects of 52, 54, 62, 63 and 101 on inflammation-related gene expression in LPS-stimulated RAW 264.7 macrophages.
Cells were treated with LPS (1μg/mL) in the absence or presence of the constituents at different concentrations for 10 h. The mRNA level was analyzed using real-time PCR; ++p<0.01, control group vs LPS-stimulated group; +p<0.05, control group vs LPS-stimulated group; **P<0.01, LPS vs LPS plus constituents-treated group. Values shown in the graphs are mean ± standard deviation (n = 3).